NCT04857866View on ClinicalTrials.gov

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

November 10, 2022

Study Completion Date

November 10, 2022

Conditions
Safety in Healthy Volunteers
Interventions
DRUG

XmAb27564

Single ascending dose of XmAb27564

DRUG

Placebo

Single dose of placebo

Trial Locations (1)

78209

ICON Early Phase Services, LLC, San Antonio

Sponsors

Collaborators (1)

ICON Clinical Research
All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

lead

Xencor, Inc.

INDUSTRY